Enrico Martin

271 Morbidity and function loss after resection of MPNST References 1. Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res . 2013;33(6):2597-2604. 2. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer . 2006;107(5):1065-1074. doi:10.1002/cncr.22098 3. Martin E, Coert JH, Flucke UE, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer . 2019;124:77-87. doi:10.1016/j. ejca.2019.10.014 4. Miao R, Wang H, Jacobson A , et al. Radiation -induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol . 2019;137:61-70. doi:10.1016/j.radonc.2019.03.015 5. Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer . 2016;56:77-84. doi:10.1016/j.ejca.2015.12.015 6. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw . 2016;14(6):758-786. 7. Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant Chemotherapy in High- Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol Off J Am Soc Clin Oncol . 2020;38(19):2178-2186. doi:10.1200/JCO.19.03289 8. Higham CS, Steinberg SM, Dombi E, et al. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma . 2017;2017:8685638. doi:10.1155/2017/8685638 9. Davis AM, Sennik S, Griffin AM, et al. Predictors of functional outcomes following limb salvage surgery for lower- extremity soft tissue sarcoma. J Surg Oncol . 2000;73(4):206-211. 10. Davis AM, Bell RS, Badley EM, Yoshida K, Williams JI. Evaluating functional outcome in patients with lower extremity sarcoma. Clin Orthop Relat Res . 1999;(358):90-100. 11. Mundinger GS, Prucz RB, Frassica FJ, Deune EG. Concomitant upper extremity soft tissue sarcoma limb-sparing resection and functional reconstruction: assessment of outcomes and costs of surgery. Hand (N Y) . 2014;9(2):196-204. doi:10.1007/s11552-013-9567-9 12. Saint-Cyr M, Langstein HN. Reconstruction of the hand and upper extremity after tumor resection. J Surg Oncol . 2006;94 (6):490 -503. doi:10.1002 / jso.20486 13. Martin E, Dullaart MJ, van de Sande MAJ, van Houdt WJ, Schellekens PPA, Coert JH. Resuscitating extremities after soft tissue sarcoma resections: Are functional reconstructions an overlooked option in limb salvage? A systematic review. Eur J Surg Oncol . 2019;in press. doi:https://doi. org/10.1016/j.ejso.2019.05.024 14. Martin E, Dullaart MJ, Verhoef C, Coert JH. A systematic review of functional outcomes after nerve reconstruction in extremity soft tissue sarcomas: A need for general implementation in the armamentarium. J Plast Reconstr Aesthetic Surg . 2020. doi:10.1016/j.bjps.2019.12.010 11